Trial Profile
Post-Marketing Surveillance of Safety and Effectiveness of Iclusig Tablets in Korean Patients With CML or Ph+ ALL Under the "Risk Management Plan"
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 09 Dec 2022
Price :
$35
*
At a glance
- Drugs Ponatinib (Primary)
- Indications Chronic myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- Sponsors Korea Otsuka Pharmaceutical
- 02 Sep 2022 Status changed from recruiting to active, no longer recruiting.
- 15 Sep 2020 Planned End Date changed from 1 Dec 2023 to 1 Jun 2023.
- 25 Oct 2018 New trial record